Literature DB >> 15465011

N-Formylated humanin activates both formyl peptide receptor-like 1 and 2.

Masataka Harada1, Yugo Habata, Masaki Hosoya, Kazunori Nishi, Ryo Fujii, Makoto Kobayashi, Shuji Hinuma.   

Abstract

We have discovered that humanin (HN) acts as a ligand for formyl peptide receptor-like 1 (FPRL1) and 2 (FPRL2). This discovery was based on our finding that HN suppressed forskolin-induced cAMP production in Chinese hamster ovary (CHO) cells expressing human FPRL1 (CHO-hFPRL1) or human FPRL2 (CHO-hFPRL2). In addition, we found that N-formylated HN (fHN) performed more potently as a ligand for FPRL1 than HN: in CHO-hFPRL1 cells, the effective concentration for the half-maximal response (EC(50)) value of HN was 3.5nM, while that of fHN was 0.012nM. We demonstrated by binding experiments using [(125)I]-W peptide that HN and fHN directly interacted with hFPRL1 on the membrane. In addition, we found that HN and fHN showed strong chemotactic activity for CHO-hFPRL1 and CHO-hFPRL2 cells. HN is known to have a protective effect against neuronal cell death. Our findings contribute to the understanding of the mechanism behind HN's function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465011     DOI: 10.1016/j.bbrc.2004.09.046

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  41 in total

1.  Potent humanin analog increases glucose-stimulated insulin secretion through enhanced metabolism in the β cell.

Authors:  Regina Kuliawat; Laura Klein; Zhenwei Gong; Marianna Nicoletta-Gentile; Anjana Nemkal; Lingguang Cui; Claire Bastie; Kai Su; Derek Huffman; Manju Surana; Nir Barzilai; Norman Fleischer; Radhika Muzumdar
Journal:  FASEB J       Date:  2013-08-30       Impact factor: 5.191

2.  Neuroprotective effect of humanin on cerebral ischemia/reperfusion injury is mediated by a PI3K/Akt pathway.

Authors:  Xingshun Xu; Chu Chang Chua; Jinping Gao; Kao-Wei Chua; Hong Wang; Ronald C Hamdy; Balvin H L Chua
Journal:  Brain Res       Date:  2008-06-16       Impact factor: 3.252

3.  Humanin Derivatives Inhibit Necrotic Cell Death in Neurons.

Authors:  Aviv Cohen; Jenny Lerner-Yardeni; David Meridor; Roni Kasher; Ilana Nathan; Abraham H Parola
Journal:  Mol Med       Date:  2015-06-04       Impact factor: 6.354

Review 4.  The emerging role of the mitochondrial-derived peptide humanin in stress resistance.

Authors:  Kelvin Yen; Changhan Lee; Hemal Mehta; Pinchas Cohen
Journal:  J Mol Endocrinol       Date:  2013-01-11       Impact factor: 5.098

Review 5.  Molecular biology for formyl peptide receptors in human diseases.

Authors:  Yongsheng Li; Duyun Ye
Journal:  J Mol Med (Berl)       Date:  2013-02-13       Impact factor: 4.599

Review 6.  Humanin: Functional Interfaces with IGF-I.

Authors:  J Xiao; S-J Kim; P Cohen; K Yen
Journal:  Growth Horm IGF Res       Date:  2016-04-07       Impact factor: 2.372

Review 7.  Mitochondrially derived peptides as novel regulators of metabolism.

Authors:  Su-Jeong Kim; Jialin Xiao; Junxiang Wan; Pinchas Cohen; Kelvin Yen
Journal:  J Physiol       Date:  2017-07-18       Impact factor: 5.182

Review 8.  Therapeutic Potential of Lipoxin A4 in Chronic Inflammation: Focus on Cardiometabolic Disease.

Authors:  Ting Fu; Muthukumar Mohan; Eoin P Brennan; Owen L Woodman; Catherine Godson; Phillip Kantharidis; Rebecca H Ritchie; Cheng Xue Qin
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-17

Review 9.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

10.  Humanin: a novel central regulator of peripheral insulin action.

Authors:  Radhika H Muzumdar; Derek M Huffman; Gil Atzmon; Christoph Buettner; Laura J Cobb; Sigal Fishman; Temuri Budagov; Lingguang Cui; Francine H Einstein; Aruna Poduval; David Hwang; Nir Barzilai; Pinchas Cohen
Journal:  PLoS One       Date:  2009-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.